Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

CompletedOBSERVATIONAL

Enrollment

44,671

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

July 30, 2025

Study Completion Date

July 30, 2025

Conditions

Type 2 DiabetesMajor Adverse Cardiac EventsCardiovascular (CV) Risk

Interventions

DRUG

Tirzepatide

New use of tirzepatide dispensing claim is used as the exposure.

DRUG

Dulaglutide

New use of dulaglutide dispensing claim is used as the reference.

Trial Locations (1)

Brigham and Women's Hospital, Boston

All Listed Sponsors

lead

Brigham and Women's Hospital

OTHER

NCT07088718 - Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data | Biotech Hunter | Biotech Hunter